PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33449813-1	2021	PURPOSE: Approximately 20% of patients with TP53-mutant myelodysplastic syndromes (MDS) achieve complete remission (CR) with hypomethylating agents.	hypomethylating agents	125-147	tumor protein p53	Homo sapiens	44-48
33959953-7	2021	Furthermore, we observed an association between WNT/beta-catenin factors and treatment response to hypomethylating agents (HMAs) in a cohort of patients with MDS/myeloproliferative neoplasms (MPNs).	hypomethylating agents	99-121	catenin beta 1	Homo sapiens	52-64
32171069-2	2020	The BCL-2 inhibitor, venetoclax, has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older adults for whom chemotherapy is not suitable with newly diagnosed acute myeloid leukaemia.	hypomethylating agents	82-104	BCL2 apoptosis regulator	Homo sapiens	4-9
33919958-4	2021	The Bcl-2 inhibitor venetoclax, in combination with hypomethylating agents or low dose cytarabine, has produced impressive results for newly diagnosed AML, while its role in R/R disease is not well defined yet.	hypomethylating agents	52-74	BCL2 apoptosis regulator	Homo sapiens	4-9
32873914-0	2021	Wilm"s Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation.	hypomethylating agents	48-70	WT1 transcription factor	Homo sapiens	0-14
32601337-0	2020	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.	hypomethylating agents	102-124	cd70	None	10-14
32872475-9	2020	The use of hypomethylating agents had no effect toward expression of human VDR transcripts, but it increased expression of the VDR-target gene, CYP24A1.	hypomethylating agents	11-33	vitamin D receptor	Homo sapiens	127-130
32872475-9	2020	The use of hypomethylating agents had no effect toward expression of human VDR transcripts, but it increased expression of the VDR-target gene, CYP24A1.	hypomethylating agents	11-33	cytochrome P450 family 24 subfamily A member 1	Homo sapiens	144-151
32628327-0	2020	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.	hypomethylating agents	15-37	fms related receptor tyrosine kinase 3	Homo sapiens	41-45
32587297-0	2020	Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.	hypomethylating agents	27-49	sirtuin 6	Homo sapiens	14-19
33407852-0	2021	Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.	hypomethylating agents	39-61	microRNA 125a	Homo sapiens	0-14
32905646-4	2021	Pre-treatment with hypomethylating agents, 5-azacytidine, or decitabine, restored SLC22A4 mRNA expression, increased cellular uptake of Ara-C, and was associated with increased cellular sensitivity to Ara-C compared with vehicle-treated cells.	hypomethylating agents	19-41	solute carrier family 22 member 4	Homo sapiens	82-89
33415012-7	2020	In addition, high TET2 VAF was associated with an increased response to hypomethylating agents relative to low TET2 VAF (P = 0.009).	hypomethylating agents	72-94	tet methylcytosine dioxygenase 2	Homo sapiens	18-22
32445940-0	2020	DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.	hypomethylating agents	90-112	DNA methyltransferase 3 alpha	Homo sapiens	0-6
32251497-2	2020	Although typically associated with favorable prognosis, the beneficial impact of NPM1+ decreases with increasing age in patients treated with standard intensive chemotherapy (IC) or hypomethylating agents (HMAs).	hypomethylating agents	182-204	nucleophosmin 1	Homo sapiens	81-85
30623427-0	2019	The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.	hypomethylating agents	87-109	BCL2 apoptosis regulator	Homo sapiens	4-9
30623427-0	2019	The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.	hypomethylating agents	87-109	NFE2 like bZIP transcription factor 2	Homo sapiens	40-44
30623427-1	2019	Induction of reactive oxygen species (ROS), an important process for the cytotoxicity of various acute myeloid leukemia (AML) therapies including hypomethylating agents (HMAs), concurrently activates the NF-E2-related factor 2 (Nrf2) antioxidant response pathway which in turn results in induction of antioxidant enzymes that neutralize ROS.	hypomethylating agents	146-168	NFE2 like bZIP transcription factor 2	Homo sapiens	204-226
30623427-1	2019	Induction of reactive oxygen species (ROS), an important process for the cytotoxicity of various acute myeloid leukemia (AML) therapies including hypomethylating agents (HMAs), concurrently activates the NF-E2-related factor 2 (Nrf2) antioxidant response pathway which in turn results in induction of antioxidant enzymes that neutralize ROS.	hypomethylating agents	146-168	NFE2 like bZIP transcription factor 2	Homo sapiens	228-232
29532991-1	2018	It has been recently demonstrated that high pre-treatment levels of miR-29b positively correlated with the response of patients with acute myeloid leukaemia (AML) to hypomethylating agents.	hypomethylating agents	166-188	microRNA 29b-1	Homo sapiens	68-75
34945003-6	2021	In addition, PARPi can enhance the efficacy of other agents, particularly alkylating agents, TOP1 poisons, and hypomethylating agents, that induce lesions ordinarily repaired via PARP1-dependent mechanisms.	hypomethylating agents	111-133	poly(ADP-ribose) polymerase 1	Homo sapiens	179-184
33818418-1	2021	The hypomethylating agents (HMAs) azacytidine (AZA) and decitabine (DAC) are usually administered after the failure of erythropoietin-stimulating agents for lower-risk myelodysplastic syndromes (LR-MDS).	hypomethylating agents	4-26	erythropoietin	Homo sapiens	119-133
34461985-0	2021	Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.	hypomethylating agents	86-108	BCL6 corepressor	Homo sapiens	38-42
34551907-1	2021	PURPOSE: Azacitidine and decitabine are hypomethylating agents (HMAs), that is, inhibit and deplete DNA methyltransferase 1 (DNMT1).	hypomethylating agents	40-62	DNA methyltransferase 1	Homo sapiens	100-123
34551907-1	2021	PURPOSE: Azacitidine and decitabine are hypomethylating agents (HMAs), that is, inhibit and deplete DNA methyltransferase 1 (DNMT1).	hypomethylating agents	40-62	DNA methyltransferase 1	Homo sapiens	125-130
34364821-0	2021	The Real-Life Efficacy of Fixed-Dose Hypomethylating Agents in Older Patients With Acute Myeloid Leukemia: A 10-Year Experience.	hypomethylating agents	37-59	immunoglobulin kappa variable 6D-21 (non-functional)	Homo sapiens	107-111
34314648-1	2021	OBJECTIVE: Hypomethylating agents (HMAs) have been reported to target the Sonic Hedgehog (Shh) signaling pathway in myelodysplastic syndrome (MDS).	hypomethylating agents	11-33	sonic hedgehog signaling molecule	Homo sapiens	74-88
34314648-1	2021	OBJECTIVE: Hypomethylating agents (HMAs) have been reported to target the Sonic Hedgehog (Shh) signaling pathway in myelodysplastic syndrome (MDS).	hypomethylating agents	11-33	sonic hedgehog signaling molecule	Homo sapiens	90-93
34291333-0	2021	miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.	hypomethylating agents	31-53	microRNA 23a	Homo sapiens	0-7
34771553-5	2021	Herein, we discuss the features of monoallelic and biallelic TP53 mutations within MDS, their corresponding carcinogenic mechanisms, their predictive value in current standard treatments including hypomethylating agents, allogeneic hematopoietic stem cell transplantation, and lenalidomide, together with the latest progress in TP53-targeted therapy strategies, especially MDS clinical trial data.	hypomethylating agents	197-219	tumor protein p53	Homo sapiens	61-65
35628480-0	2022	Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents.	hypomethylating agents	170-192	phosphatase and tensin homolog	Homo sapiens	24-28
35613022-6	2022	RESULTS: SALL4 up-regulation after treatment with hypomethylating agents was observed in 10 of 25 patients (40%) in cohort 1 and in 13 of 43 patients (30%) in cohort 2 and was associated with a worse outcome.	hypomethylating agents	50-72	spalt like transcription factor 4	Homo sapiens	9-14
35628480-0	2022	Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents.	hypomethylating agents	170-192	tissue factor pathway inhibitor	Homo sapiens	33-36
35628480-0	2022	Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents.	hypomethylating agents	170-192	MDM2 proto-oncogene	Homo sapiens	66-70
35628480-8	2022	In conclusion, epigenetic and epi-transcriptomic dysregulation of PTEN and MDM2 were associated with resistance to hypomethylating agents.	hypomethylating agents	115-137	tissue factor pathway inhibitor	Homo sapiens	30-33
35628480-8	2022	In conclusion, epigenetic and epi-transcriptomic dysregulation of PTEN and MDM2 were associated with resistance to hypomethylating agents.	hypomethylating agents	115-137	phosphatase and tensin homolog	Homo sapiens	66-70
35628480-8	2022	In conclusion, epigenetic and epi-transcriptomic dysregulation of PTEN and MDM2 were associated with resistance to hypomethylating agents.	hypomethylating agents	115-137	MDM2 proto-oncogene	Homo sapiens	75-79
34966123-1	2022	PURPOSE OF REVIEW: Venetoclax is a BCL-2 inhibitor that was approved in combination therapy with hypomethylating agents or low dose cytarabine for newly diagnosed acute myeloid leukemia (AML).	hypomethylating agents	97-119	BCL2 apoptosis regulator	Homo sapiens	35-40